- English
Il nostro Comitato Scientifico è guidato da esperti di fama internazionale provenienti da Harvard Medical School e dal Brigham and Women’s Hospital di Boston.
Unendo competenze d’eccellenza in medicina rigenerativa, precision health e intelligenza artificiale, garantiamo che ogni protocollo KinAura sia al tempo stesso innovativo, validato scientificamente ed efficace nella pratica clinica.
An international team of medical and scientific leaders ensuring every KinAura protocol meets
the highest standards of safety, evidence, and effectiveness.
Professor of Radiation Oncology at Harvard Medical School, Dr. Mak serves as Director of Clinical Innovation, and Director of Patient Safety and Quality in the Department of Radiation Oncology at Brigham and Women’s Hospital / Dana-Farber Cancer Institute.
his research focuses on developing clinically relevant biomarkers of tumor response and radiation-induced toxicity in lung cancer, leveraging artificial intelligence and advanced imaging technologies.
He also explores the clinical application of AI to enhance the quality and effectiveness of cancer therapy through the design and implementation of clinical trials. His work has been supported by the National Cancer Institute (U01: Site PI) and recognized by the Radiological Society of North America.
Dr. Mak is also a distinguished member of the KinAura International Scientific Board, where he contributes his expertise in oncology, AI-driven biomarkers, and patient-centered innovation to guide the development of cutting-edge regenerative health protocols.
Professor at Harvard Medical School and director of the AI in Medicine Program at Mass General Brigham (https://aim.mgh.harvard.edu/), Prof. Hugo Aerts is a global leader in applying artificial intelligence to personalized medicine DFHCCAIM.
He is also a key author of FAHR-Face, a foundation AI model trained on millions of face photographs to assess biological aging and survival risk, with clinical validation in cancer cohorts.
